RegenoCELL Therapeutics, Inc.
| OTC Markets: RCLL
RegenoCELL Therapeutics, Inc. develops a stem-cell therapy business for the treatment of congestive heart failure and peripheral artery disease. It utilizes adult stem cells, derived from the patient's own blood, which eliminates the ethical and safety concerns associated with embryonic and umbilical cord blood stem cells. The stem cell therapy is either delivered through a catheter or injected directly into the myocardium. The company was founded by Scott Massey on February 1, 2002 and is headquartered in Natick, MA.